Tiafeng Capital is committed to identifying five sub-sectors of the global life sciences and biotechnology sector, which are Monoclonal antibody drugs and therapy, Genomic signature, protein sequence analysis, and personalized diagnostics and medicine, Mobile medical and Big Data analytics, Innovated medical devices such as robotic surgical system, and High-tech medical materials. The team comprises of a group of PhDs in life sciences, assisted by an independent advisory board who have a deep background in clinical practice.